Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimekizumab - UCB

Next Previous
Drug Profile

Bimekizumab - UCB

Alternative Names: Anti-IL-17-mAb-UCB; Anti-IL-17-monoclonal-antibody-UCB; Anti-interleukin-17-monoclonal-antibody-UCB; bimekizumab-bkzx; BIMZELX; Bimzelx; BKZ; CDP-4940; UCB-4940

Latest Information Update: 22 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Axial spondyloarthritis; Erythrodermic psoriasis; Plaque psoriasis; Pustular psoriasis
  • Registered Ankylosing spondylitis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Psoriatic arthritis
  • Phase III Palmoplantar pustulosis
  • No development reported Psoriasis
  • Discontinued Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 09 Aug 2026 UCB Biopharma completes the phase III BE MOVING trial in Ankylosing spondylitis in USA, Bulgaria, Czech Republic, Germany, Hungary, Poland, Belgium, China, France, Japan, the Netherlands, Spain, Turkey and UK (SC) (NCT04436640)
  • 29 Jul 2026 UCB Biopharma completes enrolment in a phase-III clinical trials in Hidradenitis suppurativa (In children, In adolescents, Treatment-resistant) in Germany, Poland (SC) (NCT06921850)
  • 22 Jul 2026 UCB Biopharma completes the Phase-III BE HEARD EXT trials in Hidradenitis suppurativa (Treatment-experienced) in Netherlands, Italy, Ireland, Belgium, Australia, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Poland, Spain, Turkey, UK, Japan (SC) (NCT04901195)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top